Dutton Associates Announces Investment Opinion: Neoprobe Rating Maintained At Strong...

Dutton Associates Announces Investment Opinion: Neoprobe Rating Maintained At Strong Speculative Buy By Dutton Associates

ROSEVILLE, Calif.--(Business Wire)--
Dutton Associates continues coverage of Neoprobe Corporation
(OTCBB:NEOP), maintaining its rating at Strong Speculative Buy with a
higher price target of $1.50. The 14-page report by Dutton senior
analyst Dennis C. Fisher, CFA is available at www.jmdutton.com as well
as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other
leading financial portals.

We continue to project that Neoprobe will become profitable in
2009 and report untaxed EPS of $0.07 for the full year. The driver for
our expected earnings continues to be commercialization of
Lymphoseek(R), a proprietary radiopharmaceutical being developed for
the identification of sentinel lymph nodes during sentinel lymph node
biopsies (SLNBs) to stage several solid tumor types including breast,
melanoma, head and neck, prostrate, gastrointestinal and colorectal
cancers. The Company reported positive Phase II clinical results for
Lymphoseek and the first clinical sites have begun recruiting and
screening patients for inclusion in the breast cancer and melanoma
trials scheduled to begin this month. A second Phase III trial in head
and neck cancers is set to launch at mid-year. These Phase III trials
have been designed to procure a "first-in-class" label from the FDA
that supports the use of Lymphoseek in sentinel lymph node biopsy
(SLNB) procedures, which would likely facilitate market acceptance and
more rapid uptake in sales. The molecule has important clinical
advantages over existing radiopharmaceuticals that are currently used
off-label for SLNBs, and, as the first radiopharmaceutical that may be
specifically labeled for the indication, may also have the additional
advantage of securing insurance reimbursement for hospital costs that
average roughly $900 per procedure. There are a number of milestones
that should help boost the stock price - all of which we anticipate
will occur over the course of the next 12 months.

About Dutton Associates

Dutton Associates is one of the largest independent investment
research firms in the U.S. Its 30 senior analysts are primarily CFAs,
and have expertise in many industries. Dutton Associates provides
continuing analyst coverage of over 140 enrolled companies, and its
research, estimates, and ratings are carried in all the major
databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program
is US $35,000 prepaid for 4 Research Reports, typically published
quarterly, and requisite Research Notes. Dutton Associates received
$102,000 from the Company for 14 Research Reports with coverage
commencing on 7/26/2004. The Firm does not accept any equity
compensation. Our principals and analysts are prohibited from owning
or trading in securities of covered companies. The views expressed in
this research report accurately reflect the analyst's personal views
about the subject securities or issuer. Neither the analyst's
compensation nor the compensation received by us is in any way related
to the specific ratings or views contained in this research report or
note. Please read full disclosures and analyst background at
www.jmdutton.com before investing.

Dutton Associates
John Dutton, President, 916/960-0623

Copyright Business Wire 2008